Kura Oncology (KURA)
(Delayed Data from NSDQ)
$21.09 USD
+0.31 (1.49%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $21.08 -0.01 (-0.05%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for Kura Oncology, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 424 | 438 | 518 | 633 | 237 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 9 | 8 | 4 | 4 | 3 |
Total Current Assets | 432 | 446 | 522 | 637 | 240 |
Net Property & Equipment | 2 | 3 | 3 | 2 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 8 | 4 | 4 | 2 | 2 |
Total Assets | 449 | 456 | 534 | 647 | 242 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 34 | 22 | 22 | 23 | 15 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 3 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 35 | 24 | 22 | 26 | 16 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 9 | 9 | 0 | 4 | 7 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 52 | 36 | 27 | 36 | 23 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,120 | 997 | 941 | 913 | 431 |
Retained Earnings | -721 | -569 | -433 | -303 | -213 |
Other Equity | -1 | -8 | -2 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 397 | 420 | 507 | 611 | 219 |
Total Liabilities & Shareholder's Equity | 449 | 456 | 534 | 647 | 242 |
Total Common Equity | 397 | 420 | 507 | 611 | 219 |
Shares Outstanding | 74.20 | 66.90 | 66.50 | 56.70 | 45.30 |
Book Value Per Share | 5.35 | 6.28 | 7.62 | 10.77 | 4.83 |
Fiscal Year End for Kura Oncology, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 527 | 424 | 453 | 477 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 11 | 9 | 7 | 9 |
Total Current Assets | NA | 538 | 432 | 460 | 486 |
Net Property & Equipment | NA | 2 | 2 | 2 | 2 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 8 | 8 | 5 | 4 |
Total Assets | NA | 554 | 449 | 474 | 495 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 31 | 34 | 26 | 22 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 32 | 35 | 28 | 24 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 9 | 9 | 9 | 9 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 1 | 1 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 49 | 52 | 44 | 35 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 1,277 | 1,120 | 1,112 | 1,105 |
Retained Earnings | NA | -771 | -721 | -679 | -640 |
Other Equity | NA | -1 | -1 | -4 | -5 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 505 | 397 | 430 | 460 |
Total Liabilities & Shareholder's Equity | NA | 554 | 449 | 474 | 495 |
Total Common Equity | 0 | 505 | 397 | 430 | 460 |
Shares Outstanding | 76.10 | 76.10 | 74.20 | 74.20 | 68.40 |
Book Value Per Share | 0.00 | 6.64 | 5.35 | 5.79 | 6.72 |